Af­ter painful flop late last year, Al­lakos re­veals new PhI­II da­ta and piv­ots to new in­di­ca­tions

Sev­er­al years af­ter se­cur­ing $100 mil­lion cash in an NEA-led mega round to pur­sue its lead drug in cer­tain al­ler­gic and in­flam­ma­to­ry dis­eases, one-time high fli­er Al­lakos is now piv­ot­ing its R&D ef­forts in the can­di­date to oth­er dis­eases and an­oth­er po­ten­tial can­di­date.

The Cal­i­for­nia-based al­ler­gy and in­flam­ma­tion play­er re­port­ed da­ta from 24 weeks out in the Phase III tri­al EoDyssey, which was in­ves­ti­gat­ing lead drug can­di­date lirente­limab in pa­tients with con­firmed eosinophilic duo­deni­tis — a chron­ic in­flam­ma­to­ry dis­ease char­ac­ter­ized by in­flam­ma­tion in the stom­ach and part of the small in­tes­tine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.